After receiving US FDA approval for clonidine hydrochloride extended release tablets, Ajanta Pharma launched the product in 0.1 mg dosage in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc. It is a bioequivalent generic version of Kapvay tablets and it has launched the product in 0.1mg dosage.

Clonidine hydrochloride extended release tablets is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 39 ANDAs of which it has 22 final ANDA approvals, 2 tentative approval and 15 ANDAs under review with US FDA. Till date, it has launched 16 products in the US market.

Ajanta scrip moved up by Rs.6.65 to Rs.1,349.60 on BSE in the morning today. The scrip touched to yearly highest level at Rs.1,922 on December 8, 2016 and lowest level at Rs.1,106 on August 22, 2017.